KU-32, a Novel Drug for Diabetic Neuropathy, Is Safe for Human Islets and Improves In Vitro Insulin Secretion and Viability
Figure 5
KU-32 did not alter blood glucose and insulin levels in vivo. (a) Weekly blood glucose measurements demonstrate that both groups of animals were diabetic, and levels were not affected by KU-32 administration ( vehicle- and 16 KU-32-treated mice). (b) At the termination of the study serum insulin levels were not different between the vehicle- and KU-32-treated mice ( vehicle- and 4 KU-32-treated mice).
